Moleculin Biotech MBRX 深 沪
等待开盘 10-16 09:30:00 美东时间
0.3701
-0.041
-9.95%
华盛通- 最 高0.426
- 今 开0.42
- 成交量 33.61万股
- 最 低 0.3701
- 昨 收 0.411
- 总市值 7544.777178
- 52周最高 15.75
- 市盈率 静 --
- 换手率 1648.56%
- 52周最低 0.1614
- 委 比 33.04%
- 总股本 2.04万
- 历史最高 21555.00
- 量 比 1.35
- 振 幅 13.60%
- 历史最低 0.1614
- 每 手 1
- 风险率 3.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Completes Enrollment in Pivotal AML Trial
Moleculin Biotech ( ($MBRX) ) has issued an announcement. On September 29, 2026...
09-29 21:16
Moleculin Highlights Annamycin Cardiac Safety in New Analysis
An update from Moleculin Biotech ( ($MBRX) ) is now available. On September 28,...
09-28 19:24
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Moleculin Biotech announced the publication of a peer-reviewed analysis in Frontiers in Cardiovascular Medicine, demonstrating the cardiac safety of Annamycin across five clinical trials involving 90 patients. The study found no evidence of treatment-related cardiotoxicity, even at cumulative doses exceeding traditional anthracycline limits. Key findings included no significant change in LVEF, no relationship between cumulative dose or age and LV...
09-28 11:00
Moleculin Highlights Immune-Driven Annamycin Pancreatic Cancer Data
Moleculin Biotech ( ($MBRX) ) has provided an update. On September 25, 2026, Mo...
09-26 01:27
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Moleculin Biotech's Annamycin shows potential in pancreatic cancer treatment by demonstrating antitumor activity partially mediated by CD8+ T cells, suggesting a possible immune-mediated mechanism alongside direct cytotoxic effects. This finding highlights its potential to target "cold" tumors, which are typically resistant to immune therapies. The research, presented at the AACR Conference on Pancreatic Cancer, underscores Annamycin's dual作用 mec...
09-25 17:05
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Moleculin Biotech, Inc. announced that the Mexican Patent Office granted Patent No. 436849, strengthening the company's global intellectual property portfolio for its proprietary lung-targeted liposomal Annamycin technology. This patent supports Moleculin's strategy to build a robust worldwide IP estate around Annamycin, a highly efficacious and well-tolerated anthracycline currently being evaluated in the pivotal MIRACLE trial for relapsed or re...
09-23 12:25
美股异动丨Moleculin Biotech盘前续涨约6%，临床数据预期与学术会议催化
格隆汇9月15日｜美股生物医药股Moleculin Biotech(MBRX.US盘前继续上涨约6%，延续了前一交易日的反弹势头。 消息面上，公司于9月14日宣...
09-15 17:08
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
Moleculin Biotech, Inc. announced that its pre-recorded presentation from the H.C. Wainwright Global Investment Conference is now available on-demand. The presentation, led by CEO Walter Klemp, covers the company's recent developments, including its lead program, Annamycin, a potential treatment for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Annamycin is currently in Phase 2/3 trials. The co...
09-11 12:30
Moleculin Biotech Updates Investors with New Presentation
Moleculin Biotech ( ($MBRX) ) has shared an update. On August 31, 2026, Molecul...
09-01 05:53
美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
08-31 18:14
